Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board

SAN DIEGO, CAJuly 10, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that Ellen Embrey, B.S., has joined its strategic advisory board. Embrey earned a bachelor’s degree from Virginia Tech and was twice awarded the Department of Defense (DOD) Distinguished Civilian Service Award. Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board.

Embrey acted as the Assistant Secretary of Defense for Health Affairs and the Director of TRICARE Management Activity during the presidential transition period in 2009-2010. She was also the Deputy Assistant Secretary of Defense for Force Health Protection and Readiness, leading significant changes in DOD policies and programs affecting deployment and combat casualty medicine, health promotion and preventive medicine, medical readiness and public health emergency preparedness and response.

“I am passionate about discovering the best possible health promotion, prevention and treatment services for America’s service members, veterans, and their families,” said Embrey. “Pathway’s cutting-edge testing provides an exquisite opportunity for care providers in both DOD and VA systems of care to understand and leverage patient-specific genetic information to design effective and personalized prevention and treatment programs for common health issues such as obesity, depression, pain management, and cancer.”

Embrey is currently CEO of Stratitia Inc., a firm providing medical logistics, scientific and technical subject matter experts, program and project management, management consulting, strategic planning, and health facility planning and design services in the healthcare, IT management, and emergency response preparedness sectors.

“We’re very fortunate to have someone as widely respected and accomplished as Ellen on our advisory board,” said Jim Plante, Pathway Genomics CEO. “Now that Pathway is a certified contractor to the federal government, having the benefit of Ellen’s guidance and experience are invaluable in helping to ensure the military and veteran community has widespread availability of these critical new healthcare tools.”

Event Marks One-Year Anniversary of US Supreme Court Decision to Ban Human Gene Patenting

Dr. Judith A. Salerno, president and CEO of Susan G. Komen, and Jim Plante, founder and CEO of Pathway Genomics

SAN DIEGO, CAJune 17, 2014  – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, last week co-hosted a fundraiser benefiting Susan G. Komen. Jim Plante, founder and CEO of Pathway Genomics, and Ryan Kavanaugh, CEO of Relativity, were the hosts of the event, titled Pathway to the Cure. The fundraiser, held in Santa Monica, California, raised more than $300,000 through generous donations made by attendees of the event.

“We’re working with Susan G. Komen to help spread awareness about breast cancer, and to help as many women as we can in the battle against this disease,” said Plante. “We’re truly working to save lives, and ultimately prevent breast cancer forever.”

Attended by notable celebrities, such as Adrian Grenier and Sophia Bush, the event’s entertainment for the evening was provided by DJ Zen Freeman and DJ Nikki Pennie, and included a musical performance by world-renowned artist Kesha, whose hits include “Tik Tok,” and the wildly popular “Timber,” a collaboration with rapper Pitbull.

World-renowned artist Kesha performing at Pathway to the Cure.

“This was an extraordinary event. We are grateful for the commitment and generosity of supporters such as Relativity and Pathway Genomics that will help us save lives in California and around the world, ” said Susan G. Komen president and CEO, Judith A. Salerno, M.D., M.S.

The fundraiser comes at the one-year anniversary of the U.S. Supreme Court’s unanimous decision to ban the patenting of naturally occurring genes, such as BRCA, the gene linked to breast cancer.

“We firmly believe that genetic testing for the risk of breast cancer is every person’s right and should not be overpriced and monopolized by massive corporations,” said Plante. “Pathway’s BRCA test price and our BRCA One for One program is a testament to this dedication to serve those who cannot afford this potentially life-saving test.”

Earlier this month, Pathway Genomics launched its next-generation sequencing and deletion/duplication analysis, BRCATrueTM, which can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry. To enhance the accessibility of the test, the company also launched the first-of-its-kind BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.

To learn more about BRCATrue, visit www.pathway.com/brcatrue. For more details about the BRCA One for One program, visit www.brcaoneforone.com.

Pathway Genomics today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.

“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO.

Pathway Genomics recently began offering BRCATrue™, its genetic test to help individuals understand their genetic risk for developing breast, ovarian and other types of cancers. It also launched its BRCA One for One™ program under which Pathway Genomics will provide millions of dollars of free testing to uninsured women. Additionally, as another step in its fight against breast cancer, Pathway Genomics teamed up with Relativity Media last week to co-host a VIP fundraiser in Los Angeles benefiting Susan G. Komen in support of breast cancer testing and awareness.

“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO. “Given their pattern of filing lawsuits against other companies broadening access to this life-saving technology in clear disregard of the Supreme Court’s decision last year, this lawsuit is not unexpected. We do not infringe on any valid patent claims and are prepared to vigorously defend ourselves.”

BRCATrue is a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.

“We believe that no corporation should have a monopoly over an individual’s genes. Every person should have access to vital information about their own body,” said Plante.

To enhance the accessibility of this important genetic test, Pathway Genomics has developed the BRCA One for One program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.

“We are on a mission to make genetic testing more accessible and affordable, especially testing related to cancer screening, one of the leading causes of death in the world. We believe that no corporation should have a monopoly over an individual’s genes. Every person should have access to vital information about their own body,” said Plante.

BRCATrue offers physicians an easy to interpret and clinically actionable report, advanced variant classification, as well as a rapid 2-week turnaround time. BRCATrue is the first step of many that will occur this year to demonstrate Pathway Genomics’ leadership in clinical genomics and commitment to having the most comprehensive cancer-testing menu. To learn more about BRCATrue, visit www.pathway.com/brcatrue. For more details about the BRCA One for One program, visit www.brcaoneforone.com.

Commitment to Sharing Genetic Information: Pathway Genomics Supports the Free the Data Movement

Today, Myriad and other labs hold their clinically-observed genetic variants in proprietary databases that are not freely accessible to the medical community. Pathway Genomics agrees with the Free the Data movement – these mutations should not be trade secrets. By broadening access and sharing genetic information, we can collectively harness the power of the genome to improve our understanding of disease and improve healthcare for everyone. Providing broad access to genetic testing will allow the medical community to collectively diagnose disease better, faster and cheaper; offer patients more effective healthcare and reduce costs to the healthcare system. Pathway Genomics supports the Free the Data movement and will make its BRCA1 and BRCA2 data available on ClinVar. For more information about the Free the Data movement, visit www.free-the-data.org.

Pathway Genomics today announced it has launched BRCATrueTM, a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.

To enhance the accessibility of this important genetic test, Pathway Genomics has developed the BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.

“Pathway’s mission is to ensure that people in need receive genetic testing regardless of their economic or insurance status,” said Jim Plante, Pathway Genomics’ founder and CEO. “Offering the industry’s best BRCA genetic test and making it accessible to a wide range of people is a vital objective in this mission.”

Recent studies show that up to 80 percent of families with multiple cases of breast and ovarian cancer have been attributed to BRCA1/2 mutations. Mutations in BRCA genes can occur in men and women across all ethnicities, and although anyone can have mutations in one of the BRCA genes, some groups are more likely to be affected such as those with a family history of cancer and people of Ashkenazi Jewish descent.

“One out of every eight women will be affected by breast cancer in her lifetime,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “In the history of the medical community, no clinical laboratory has offered such an unprecedented program as BRCA One for One. By making our test more accessible, we aim to make a substantial impact in the prevention of breast cancer and help further raise awareness by partnering with global patient advocacy organizations.”

BRCATrue offers physicians an easy to interpret and clinically actionable report, advanced variant classification, as well as a rapid 2-week turnaround time. BRCATrue is the first step of many that will occur this year to demonstrate Pathway Genomics’ leadership in clinical genomics and commitment to having the most comprehensive cancer-testing menu. To learn more about BRCATrue, visit www.pathway.com/brcatrue. For more details about the BRCA One for One program, visit www.brcaoneforone.com.

New members include acclaimed genetic counselors Jill Davies, M.S., CCGC, director of genetics and genomics at Medcan Clinic, and Elissa Levin, M.S., CGC, assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai

 

 MedMtSinai

 

Pathway Genomics has added industry-leading genetic counselors Jill Davies, M.S., CCGC, and Elissa Levin, M.S., CGC, to its genetic advisory board.

“Collaborating with expert genetic counselors is a critical part of Pathway’s dedication to providing clinical genetic information to patients and their physicians. Part of that dedication is to help patients learn about their genetic results through a genetic counselor.”

Linda Wasserman, M.D., Ph.D.
Laboratory Director, Pathway Genomics
Former Director of the Clinical Cancer
Genetics Care Unit, UC San Diego Moores Cancer Center

With more than 10 years as a genetic counselor, Jill Davies, M.S., CCGC, is the current director of genetics and genomics at Medcan Clinic, where she has developed a leading-edge genetics program with a range of services. Her special interest is in the role of genetics in primary care and preventive medicine, focusing on bringing the most advanced genetics knowledge to individuals to help them optimize health and manage risk for disease. As the co-investigator on the Personal Genome Project Canada (PGPC), in 2012 she became the first Canadian to have her whole genome sequenced as part of this project. Davies is an active member of the Ontario Personalized Medicine Network, the National Society of Genetic Counselors and is a Canadian board-certified genetic counselor.

Elissa Levin, M.S., CGC, is the head of Genomics and Integrative Health Innovations and assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. Previously she was at Life Technologies, where she developed and led the clinical support services department, providing clinical genomics expertise to the global organization. Levin began her career working in academic medical centers where she provided clinical genetic counseling for the Division of General and Metabolic Genetics at the University of California San Francisco and coordinated a multicenter, NIH-funded trial on the genetic basis of congenital heart disease at the Children’s Hospital of Philadelphia.

Pathway Genomics’ advisory board consists of leaders in various fields including genetic counseling, oncology, pharmacogenomics, endocrinology, bioinformatics, biostatistics, behavioral genetics, nutrigenomics, and human epigenetics. To view the company’s full advisory board, visit www.pathway.com.

Pathway Genomics today announced that Nature Genetics founding editor Kevin Davies, Ph.D., has joined its scientific advisory board.

“I believe Pathway is poised to make a major contribution to clinical diagnostics and improving the wellness of millions of patients. I hope to make a modest contribution to that effort.”

Kevin Davies, Ph.D.
Author of The $1,000 Genome and Cracking the Genome
Founding Editor, Nature Genetics

“I have followed Pathway closely for many years, reporting on the launch of the company in my book, The $1,000 Genome,” said Davies. “I believe Pathway is poised to make a major contribution to clinical diagnostics and improving the wellness of millions of patients. I hope to make a modest contribution to that effort.”

A highly respected science journalist, editor, and publisher with more than 20 years of experience at the forefront of advances in genetics and medicine, Davies is currently a vice president with the American Chemical Society, the largest scientific society in the world, where he serves as publisher of Chemical & Engineering News, the society’s weekly magazine. He has also served as editor-in-chief for Cell Press and was the founding editor of Bio-IT World magazine.

“Kevin is a vital thought leader in the genomics space and his work is a significant contribution to progress in the field,”

Ardy Arianpour
Chief Strategy Officer
Pathway Genomics

“Kevin is a vital thought leader in the genomics space and his work is a significant contribution to progress in the field,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “We are exceptionally pleased to collaborate with an opinion leader of his status.”

Born in London, Davies studied biochemistry and molecular genetics at the Universities of Oxford and London before moving to the United States. He conducted postdoctoral fellowships at MIT and Harvard Medical School before moving into science publishing. Davies is the author of three popular-science books on the medical and societal implications of the genomics revolution, including Cracking the Genome and most recently The $1,000 Genome. He is a sought-after public speaker and an occasional technical consultant to the film industry, most recently serving as genetics consultant for the film Decoding Annie Parker.

Pathway Genomics’ scientific advisory board consists of leaders in various fields including oncology, pharmacogenomics, endocrinology, bioinformatics, biostatistics, behavioral genetics, nutrigenomics, and human epigenetics. To view the company’s full scientific advisory board, visit www.pathway.com.

Pathway Genomics has added Illumina NextSeq 500 systems to its force of NGS sequencers, enhancing the company’s established and highly efficient laboratory processes.

 

The NextSeq 500’s push-button operation provides a one-day turnaround time for an array of popular sequencing applications such as a single human genome, and up to 16 exomes, 20 transcriptomes, 48 gene expression samples, 20 non-invasive prenatal samples, and 96 targeted panels. Additionally, with the sequencer’s streamlined informatics, sequencing data can be run through a range of commercial pipelines.

The NextSeq 500 provides a one-day turnaround time for an array of popular sequencing applications.

Continue reading »

Pathway Genomics announced that world-renowned geneticist George Church, Ph.D., has joined its scientific advisory board. He is the founder of the Personal Genome Project, a professor of genetics at Harvard Medical School, and director of the Harvard NHGRI Center of Excellence in Genomic Science.

Dr. Church is the founder of the Personal Genome Project, a professor of genetics at Harvard Medical School, and director of the Harvard NHGRI Center of Excellence in Genomic Science.

Continue reading »

 

Pathway Genomics has added the Illumina MiSeqDx to its fleet of next-generation sequencing systems.

 

 

 

Designed and validated for the clinical market, the benchtop sequencing system will optimize the company’s ability to develop and run diagnostic applications. It enables sample multiplexing, maximizing operator efficiency and increasing throughput.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

Continue reading »

Pathway Genomics today announced the launch of Hereditary Colorectal Cancer DNA InsightSM, the company’s premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

Continue reading »